Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

  1. cardiolite.com › healthcare-professionals › reimbursementReimbursement - Cardiolite

    Download Medicare Reimbursement Guide. If you have questions related to Cardiolite ® reimbursement, please call (800) 362-2668 (Option 3) or email reimbursement@lantheus.com. Lantheus cannot guarantee coverage or payment for products or procedures.

  2. www.cardiolite.com › pdfs › Cardiolite-US-PI-513121-0619CARDIOLITE

    CARDIOLITE® is a myocardial perfusion agent indicated for: detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects) evaluating myocardial function and developing information for use in patient management decisions.

  3. CARDIOLITE® is a myocardial perfusion agent indicated for: • detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects)

  4. 16 Δεκ 2021 · A new table in the CPT book clarifies what is included in the revised codes and the new parentheticals are under these codes: 93653, 93654 and 93656. The Evaluation and Management section of the CPT book features new introductory language, revised codes and a new section with codes for principal care management services.

  5. Billing for the radiopharmaceutical agents: 1. Radiopharmaceuticals are available in unit dose or in bulk doses, the latter requiring preparation at the imaging center. Use of radiopharmaceuticals is regulated by the Nuclear Regulatory Commission (NRC) under strict procedures and guidelines.

  6. 25 Μαρ 2024 · Cardiolite package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

  7. cardiolite.com › healthcare-professionals › healthcare-professionalsCARDIOLITE® - Healthcare Professionals

    Myocardial Imaging: Cardiolite ® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing ...

  1. Γίνεται επίσης αναζήτηση για